GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ETON · Dec 31, 2025

Eton Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001437749-26-009059General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

38.22% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensity88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.42% · OPTIONAL · VALID

Operating cash generation38thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

13.16% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

104.94% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure25thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

19.29% · OPTIONAL · VALID

Gross margin13thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.gross_margin

53.46% · CORE · VALID

Operating margin88thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-1.06% · CORE · VALID

R&D intensity63thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

9.71% · OPTIONAL · VALID

SBC intensity13thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

6.89% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building
Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/8 normalizedLevel 3Sep 30, 20250/8 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20267/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
1.26%
Current
0.42%
Delta
-0.85%
Cash Generation Decreased
Previous
53.55%
Current
13.16%
Delta
-40.38%
Growth Decreased
Previous
117.54%
Current
104.94%
Delta
-12.60%
Inventory Pressure Decreased
Previous
75.05%
Current
19.29%
Delta
-55.76%
Margin Increased
Previous
34.97%
Current
53.46%
Delta
18.48%
Profitability Increased
Previous
-6.07%
Current
-1.06%
Delta
5.01%
R And D Intensity Increased
Previous
4.95%
Current
9.71%
Delta
4.76%
Sbc Intensity Increased
Previous
4.86%
Current
6.89%
Delta
2.03%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ETON Fundamental State →Has State · Eton Pharmaceuticals, Inc. →Transitioned To · ETON Fundamental State →Transitioned To · ETON CAPEX_INTENSITY_DECREASED →Transitioned To · ETON CASH_GENERATION_DECREASED →Transitioned To · ETON GROWTH_DECREASED →Transitioned To · ETON INVENTORY_PRESSURE_DECREASED →Transitioned To · ETON MARGIN_INCREASED →Transitioned To · ETON PROFITABILITY_INCREASED →Transitioned To · ETON R_AND_D_INTENSITY_INCREASED →Transitioned To · ETON SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.